Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc. (LYEL) priced its initial public offering on Jun 21, 2021 at $17.00 per share, within its $16.00–$18.00 range, raising $425M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $4.13B. Goldman Sachs was lead-left underwriter, joined by BofA Securities, J.P. Morgan and Morgan Stanley. Cooley advised the company and Latham & Watkins advised the underwriters.

Lyell Immunopharma, Inc. is a T cell reprogramming company working to treat solid tumors with adoptive cell therapy. It is building a multi-modality pipeline aimed at overcoming T cell exhaustion and the lack of durable stemness in engineered cells.

Status

IPO

Ticker

LYEL

Exchange

Nasdaq Global Select

Priced

Jun 21, 2021

IPO price

$17.00

Price range

$16.00–$18.00

Raised

$425M

Market cap at IPO price

$4.13B

First filed

May 25, 2021

Underwriters

Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley

Company counsel

Cooley

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.